Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay

Rhea-AI Summary

Precipio (NASDAQ: PRPO) announced publication of a joint study with Memorial Sloan-Kettering Cancer Center (Mar 10, 2026) validating its Bloodhound BCR::ABL1 RT-PCR assay for CML.

The study analyzed 895 samples, found 25% of patients harbored multiple BCR::ABL1 isoforms, and reports assay sensitivity to 0.001%.

The assay quantifies all four clinically relevant isoforms (p190, p210, p230, p203) on a single plate and applies the International Scale, enabling standardized, automated MRD monitoring across lab settings.

Positive

• Study analyzed 895 patient blood and bone marrow samples
• 25% of patients had multiple BCR::ABL1 isoforms detected
• Full quantification of all four clinically relevant isoforms on one assay
• Reported sensitivity to 0.001% (1 in 100,000 cells)
• Assay applies the International Scale for standardized reporting

Negative

• None.

News Market Reaction – PRPO

+3.31%

1 alert

+3.31% News Effect

+$2M Valuation Impact

$49M Market Cap

0.4x Rel. Volume

On the day this news was published, PRPO gained 3.31%, reflecting a moderate positive market reaction. This price movement added approximately $2M to the company's valuation, bringing the market cap to $49M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Samples analyzed: 895 samples Patients with multiple breakpoints: 25% Clinically relevant isoforms: 4 isoforms (p190, p210, p230, p203) +3 more

6 metrics

Samples analyzed 895 samples Peripheral blood and bone marrow samples in CML study

Patients with multiple breakpoints 25% Patients harboring multiple BCR::ABL1 breakpoints missed by single-isoform testing

Clinically relevant isoforms 4 isoforms (p190, p210, p230, p203) Bloodhound BCR::ABL1 assay detects and quantifies all four variants

Assay sensitivity 1 in 100,000 cells (0.001%) Detection limit for measurable residual disease (MRD)

Breakpoints per run 4 breakpoints All run on a single pre-plated RT-PCR plate with controls

BCR::ABL1 isoforms tested p190, p210, p230, p203 Variants simultaneously quantified in the new assay

Market Reality Check

Price: $27.50 Vol: Volume 64,784 is 2.94x th...

high vol

$27.50 Last Close

Volume Volume 64,784 is 2.94x the 20-day average of 22,054, indicating elevated trading interest pre-news. high

Technical Price at $25.65 trades above the 200-day MA of $18.79 and about 10% below the 52-week high of $28.50.

Peers on Argus

Several Diagnostics & Research peers also showed notable moves: NOTV (+15.47%), ...

3 Up 4 Down

Several Diagnostics & Research peers also showed notable moves: NOTV (+15.47%), ADVB (+14.06%), PRPH (-9.07%), BIAF (+4.95%), ISPC (+4.09%). Momentum data show 3 peers up and 4 down, suggesting mixed but active sector trading alongside PRPO’s -3.33% move.

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Full-year results	Positive	-3.9%	Reported 2025 revenue of $24.0M, up 30% year-over-year with EBITDA gains.
Jan 15	Balance sheet update	Positive	+0.0%	Repaid $1.1M advance and reduced long-term debt to under $80,000.
Dec 05	Clinical product data	Positive	-2.4%	Announced ASH presentation of BCR::ABL1 assay results from 895 samples.
Dec 04	Cybersecurity incident	Negative	-3.1%	Disclosed limited unauthorized access to historical files with no patient impact.
Nov 14	Quarterly earnings	Positive	+8.8%	Q3-2025 revenue grew 30% YoY and 20% QoQ with improved EBITDA.

Pattern Detected

PRPO has previously seen negative reactions to several positive operational updates, with some alignment on earnings strength but divergence on growth and product news.

Recent Company History

Over the last six months, Precipio reported strong financial and operational progress. Q3-2025 revenues reached $6.8M, up 30% YoY, with a +8.79% share move following earnings on Nov 14, 2025. Full-year 2025 revenues grew to $24.0M, up 30% YoY, yet the stock fell 3.89% after the Feb 24.0M update. The company also highlighted balance-sheet cleanup and showcased its BCR::ABL1 assay at ASH, but those news items saw flat to negative price reactions, framing today’s assay-publication news against a backdrop of improving fundamentals with uneven stock responses.

Market Pulse Summary

This announcement highlights peer-reviewed validation of Precipio’s Bloodhound BCR::ABL1 assay, whic...

Analysis

This announcement highlights peer-reviewed validation of Precipio’s Bloodhound BCR::ABL1 assay, which quantifies all four major isoforms and was tested on 895 CML-related samples with sensitivity down to 0.001%. It underscores potential clinical advantages in monitoring measurable residual disease and simplifying lab workflows. In context of prior news—revenue growth to $24.0M, a cleaner balance sheet, and ASH data—investors may track adoption trends, revenue contribution from this assay, and further clinical publications as key metrics to watch.

Key Terms

bcr::abl1, chronic myeloid leukemia, mrD, rt-pcr, +2 more

6 terms

bcr::abl1 medical

"Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML)."

A BCR::ABL1 fusion is a genetic abnormality where parts of two genes join to create a single hybrid gene that makes an abnormal protein driving uncontrolled growth in certain blood cancers. Investors care because this specific, identifiable target determines which drugs and diagnostic tests will work, influencing clinical trial success, drug sales and diagnostic revenue — like finding a particular lock that a new key (therapy) is built to fit.

chronic myeloid leukemia medical

"assay for Chronic Myeloid Leukemia (CML)."

A cancer of the blood-forming cells in the bone marrow that causes too many abnormal white blood cells to be produced because of a specific genetic change; left untreated it can disrupt normal blood function and the immune system. Investors watch it because the disease has clear biological targets and well-defined treatment pathways, so advances, clinical trial results, regulatory approvals, or pricing shifts for therapies can quickly change the commercial outlook for drug makers — like a new, precision brake applied to an over-revving engine.

mrD medical

"powerful tool for monitoring measurable residual disease (MRD)."

MRD stands for minimal residual disease, the tiny number of cancer cells that can remain in the body after treatment and that may not show up on routine scans. Detecting MRD is like finding a few seeds left in a garden after clearing: it helps doctors predict the chance of relapse and measure how effective a therapy is, which investors watch because MRD results can influence clinical trial success, regulatory decisions, and a drug’s market potential.

rt-pcr medical

"single, pre-plated plate run (with all controls provided) on a RT-PCR machine."

RT-PCR is a laboratory test that converts a tiny amount of genetic material from a sample into many copies so specific viral or genetic targets can be detected, like photocopying one page until you have enough to read clearly. For investors, RT-PCR matters because its accuracy, capacity, and regulatory approval drive demand for diagnostic equipment, testing services, and related supply chains, and can influence revenue and market sentiment around healthcare and biotech companies.

aml medical

"provides important diagnostic criteria for patients with AML, ALL and MPN."

AML stands for anti-money laundering — the laws, rules and internal checks that banks and businesses use to spot and stop illicit cash flows, such as proceeds from crime or funding of illegal activities. Think of it as a security checkpoint for money: investors care because poor AML controls can lead to heavy fines, frozen assets and reputational harm that hurt profits and share value, while strong controls reduce legal and operational risk.

international scale medical

"Precipio is first to apply the International Scale to create a novel assay"

International scale describes a business, product, or operation that is large enough to compete and function across multiple countries, with the systems, staff, and resources to serve customers, comply with rules, and handle risks in different markets. For investors it signals higher growth potential and diversification—like a band that tours globally rather than just locally—while also implying greater complexity, regulatory exposure, and the need for more capital and management skill.

AI-generated analysis. Not financial advice.

This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication¹ in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio’s new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML).

According to the publication’s authors: “Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings.”

Ilan Danieli, CEO of Precipio, expanded on these findings. “Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all four clinically important variants of BCR::ABL1 (isoforms). Precipio is first to apply the International Scale to create a novel assay quantifying all four variants, setting a new standard for monitoring patients with CML. Now, for the first time, clinicians can comprehensively monitor disease progression.”

The study analyzed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML, and underscores the key advantage of a single assay that delivers multiple, medically relevant data points simultaneously. The assay can be run in physician office laboratories, regional laboratories and hospitals.

Key findings in the study highlight significant advantages of the assay

1.   Multiple data points lead to better decision making

The study demonstrates that 25% of patients have multiple forms of BCR::ABL1 breakpoints that are missed because looking for all four requires laboratories to run four different assays (isoforms p190, p210, p230 and p203). No other test delivers all results from the same platform at the same time.

2.   Full Quantification establishes a new standard

Quantitative results for BCR::ABL breakpoints are crucial for the management of CML, providing clinicians a precise, standardized measurement of the disease burden, thereby enabling them to monitor the impact of treatment and detect early relapse.

Current assays on the market provide quantitative results only for one breakpoint, p210 (also called “Major transcript”), using an established International Standard (IS) scale. The absence of quantified results for all four breakpoints hinders clinicians' ability to adequately monitor patients if other isoforms other than p210 indicate recurrence.

3.   High Sensitivity for MRD

Precipio’s Bloodhound BCR::ABL assay can detect changes as low as 1 in 100,000 cells (0.001%), thereby making it a powerful tool for monitoring measurable residual disease (MRD). At these low levels, early trends in these isoforms can provide months of advanced warning time that other, less sensitive or qualitative assays may not detect.

Assay introduces new testing capabilities for laboratories

The diagnosis and therapeutic decision-making in CML depend on the detection and quantification of BCR::ABL1. Until now, no clinical assay existed that could simultaneously test multiple BCR::ABL1 isoforms and provide quantified results, therefore requiring laboratories to run separate tests for each isoform.

To address this challenge, Precipio developed the BloodHound assay, enabling laboratories to provide proper, comprehensive testing for CML patients. The assay runs all 4 breakpoints on a single, pre-plated plate run (with all controls provided) on a RT-PCR machine. Precipio’s custom-developed analysis software provides fully quantified automated results including molecular response criteria. The BCR::ABL1 test provides important diagnostic criteria for patients with AML, ALL and MPN.

The new Precipio test simplifies workflow into one assay, is standardizable across laboratories, is quantitative and, importantly, provides target genetic markers to enable monitoring disease for years over the treatment course.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

______________________________

¹ PMID: 41506866 DOI: 10.1136/jcp-2025-210447

Inquiries:

investors@precipiodx.com

+1-203-787-7888 Ext. 523

FAQ

What did Precipio (PRPO) publish about the Bloodhound BCR::ABL1 assay on March 10, 2026?

The company published a joint study confirming the Bloodhound assay quantifies all four BCR::ABL1 isoforms on one platform. According to the company, the study analyzed 895 samples, found 25% with multiple isoforms, and reported sensitivity to 0.001% for MRD monitoring.

How sensitive is Precipio's Bloodhound BCR::ABL1 test (PRPO) for MRD detection?

The Bloodhound assay detects measurable residual disease down to 0.001% (1 in 100,000 cells). According to the company, this high sensitivity can reveal early trends months before less sensitive or qualitative assays detect recurrence.

Why does the Bloodhound assay matter for clinicians monitoring CML patients (PRPO)?

It provides quantitative results for all four BCR::ABL1 isoforms in a single run, enabling comprehensive monitoring. According to the company, this prevents missed isoforms and standardizes measurements using the International Scale across laboratories.

What sample size and key finding did the Memorial Sloan-Kettering collaboration report about PRPO's assay?

The joint study evaluated 895 peripheral blood and bone marrow samples and found 25% of patients carry multiple isoforms. According to the company, that multi-isoform frequency highlights the need for a single comprehensive assay to avoid missed detections.

Can Precipio's Bloodhound BCR::ABL1 assay be run in routine clinical labs (PRPO)?

Yes — the assay runs on standard RT-PCR machines with a pre-plated format and controls, suitable for physician-office and regional labs. According to the company, integrated analysis software delivers automated, fully quantified results including molecular response criteria.